Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Posts Earnings Results, Beats Expectations By $0.04 EPS

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) posted its quarterly earnings data on Monday. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.04, Zacks reports. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.19% and a net margin of 4.83%.The business had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.48 billion.

Fresenius Medical Care AG & Co. KGaA Trading Down 0.5%

FMS traded down $0.11 during mid-day trading on Wednesday, hitting $23.90. 906,702 shares of the stock were exchanged, compared to its average volume of 685,648. The firm’s fifty day moving average is $23.44 and its two-hundred day moving average is $22.98. The company has a market cap of $12.84 billion, a PE ratio of 12.58, a PEG ratio of 4.49 and a beta of 0.77. Fresenius Medical Care AG & Co. KGaA has a 1-year low of $20.02 and a 1-year high of $27.64. The company has a current ratio of 1.20, a quick ratio of 0.86 and a debt-to-equity ratio of 0.40.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Institutional investors have recently bought and sold shares of the company. CIBC Private Wealth Group LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 398.2% during the third quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock worth $36,000 after purchasing an additional 1,103 shares during the last quarter. Arax Advisory Partners lifted its position in Fresenius Medical Care AG & Co. KGaA by 121.6% in the fourth quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after purchasing an additional 885 shares during the period. Kestra Advisory Services LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA in the fourth quarter worth approximately $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA in the 4th quarter worth approximately $58,000. Finally, Group One Trading LLC acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA in the third quarter worth $74,000. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on FMS shares. Truist Financial set a $25.00 price target on Fresenius Medical Care AG & Co. KGaA in a report on Wednesday. Citigroup reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, July 17th. Sanford C. Bernstein began coverage on Fresenius Medical Care AG & Co. KGaA in a report on Thursday, July 16th. They set a “market perform” rating on the stock. BNP Paribas Exane downgraded Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price objective for the company. in a report on Tuesday, July 28th. Finally, Zacks Research raised shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Six equities research analysts have rated the stock with a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $22.45.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.